<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555397</url>
  </required_header>
  <id_info>
    <org_study_id>Prostate Cancer (9829)</org_study_id>
    <nct_id>NCT02555397</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer</brief_title>
  <official_title>Phase 1 Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer After Definitive Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and&#xD;
      maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene&#xD;
      therapy in men with locally recurrent prostate cancer after definitive radiotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-dependent toxicity and maximum tolerated dose (MTD) of adenovirus</measure>
    <time_frame>30 days from date of adenovirus injection (defined as day 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from biochemical/clinical failure (FFF)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA doubling time (PSADT)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific and overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Association between the primary and secondary outcomes and immunological endpoints including serum IL-12 and IFN-y levels and NK cell cytolytic activity</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at a dose of 1 x 10e10 to 1 x 10e12 viral particles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5-yCD/mutTKSR39rep-hIL12</intervention_name>
    <description>Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1</description>
    <arm_group_label>Single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven local recurrence of prostate cancer at least one year after the&#xD;
             completion of definitive radiation therapy&#xD;
&#xD;
          -  Evidence of biologically active disease as demonstrated by an unequivocally rising&#xD;
             serum PSA level that is ≥ 2 ng/mL above the nadir&#xD;
&#xD;
          -  PSA &lt; 100 ng/mL&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70&#xD;
&#xD;
          -  Negative lymph nondes as established by imaging (pelvic CT or pelvic MRI)&#xD;
&#xD;
          -  No evidence of metastatic disease, as evaluated by bone scan and CT scan of the&#xD;
             abdomen and pelvis.&#xD;
&#xD;
          -  Subjects must have adequate baseline organ function as assessed by the the following&#xD;
             laboratory values:&#xD;
&#xD;
          -  Adequate renal function with serum creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/µL&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/µL&#xD;
&#xD;
          -  Hemoglobin &gt; 10.0 g/dL&#xD;
&#xD;
          -  Bilirubin &gt; 1.5 mg/dL&#xD;
&#xD;
          -  AST/SGOT and ALT/SGPT &lt; 3.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Men of child-producing potential must be willing to consent to use effective&#xD;
             contraception for at least 3 months after the gene therapy&#xD;
&#xD;
          -  Subjects must possess the ability to give informed consent and express a willingness&#xD;
             to meet all of the expected requirements of the protocol for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PSA ≥ 100 ng/mL&#xD;
&#xD;
          -  Prostate volume &gt; 100 cc&#xD;
&#xD;
          -  Pathologically positive lymph nodes or nodes &gt; 1.0 cm on imaging (nodes &gt; 1.0 cm but&#xD;
             biopsy negative are allowed.&#xD;
&#xD;
          -  Evidence of M1 metastatic disease&#xD;
&#xD;
          -  Prior invasive malignancy except for non-melanoma skin cancer within 5 years of&#xD;
             enrollment. Subjects must be disease-free for &gt; 5 years&#xD;
&#xD;
          -  Prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy&#xD;
             for any reason&#xD;
&#xD;
          -  If the subject had prior androgen deprivation therapy (ADT), the subject exhibited&#xD;
             biochemical failure while on ADT&#xD;
&#xD;
          -  Prior systemic chemotherapy for the study cancer (prior chemotherapy for a different&#xD;
             cancer is allowed; however, subjects must be &gt; 2 years post-completion of chemotherapy&#xD;
             at the time of registration. Subjects on Proscar therapy must stop to be eligible)&#xD;
&#xD;
          -  Major surgery planned within 3 months of registration&#xD;
&#xD;
          -  Severe, active co-morbidity defined as:&#xD;
&#xD;
          -  New York Health Association Class II or greater congestive heart failure or active&#xD;
             ventricular arrhythmia requiring medication&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease (COPD) exacerbation or other respiratory illness&#xD;
             requiring hospitalization within last 3 months or precluding study therapy at the time&#xD;
             of registration&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  Previous history of liver disease including hepatitis&#xD;
&#xD;
          -  Immunosuppressive therapy including systemic corticosteroids (use of inhaled and&#xD;
             topical corticosteroids is permitted)&#xD;
&#xD;
          -  Impaired immunity or susceptibility to serious viral infections&#xD;
&#xD;
          -  Allergy to any product used in the protocol. If the subject has an allergy to&#xD;
             Ciproflaxin, another antibiotic can be substituted at the discretion of the treating&#xD;
             physician&#xD;
&#xD;
          -  Serious medical or psychiatric illiness or concomitant medication, which, in the&#xD;
             judgement of the principal investigator, might interfere with the subject's ability to&#xD;
             respond to or tolerate the treatment or complete the trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hans Stricker, MD</last_name>
    <phone>3139167658</phone>
    <email>hstrick1@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Farzan Siddiqui, MD, PhD</last_name>
    <phone>3139161021</phone>
    <email>fsiddiq2@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Stricker, MD</last_name>
      <phone>313-916-7658</phone>
      <email>hstrick1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Farzan Siddiqui, MD, PhD</last_name>
      <phone>(313) 916-1021</phone>
      <email>fsiddiq2@hfhs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther. 2013 Dec;20(12):1131-9. doi: 10.1038/gt.2013.40. Epub 2013 Jul 11.</citation>
    <PMID>23842593</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Hans Stricker, MD</investigator_full_name>
    <investigator_title>Vice Chair - Urology</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Locally Recurrent</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>IL-12</keyword>
  <keyword>Adenovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

